• A
  • A
  • A
  • ABC
  • ABC
  • ABC
  • А
  • А
  • А
  • А
  • А
Regular version of the site
3
  • Today
  • Tomorrow

Tuesday, December 1

17:00

Seminar on Diversity and Development 'Internal Migration Networks and Mortality in Home Communities'

online
Illustration for news: ‘A Completely New Platform, Never Studied or Used Before’: mRNA by Pfizer vs. Sputnik V Viral Vectors

‘A Completely New Platform, Never Studied or Used Before’: mRNA by Pfizer vs. Sputnik V Viral Vectors

One of the biggest headlines of recent days has been the announcement made by Pfizer, a U.S.-based company, and BioNTech, Germany, that BNT162b2, a COVID-19 vaccine they are developing, has proved to be 90% effective in its Phase 3 clinical trial. The news was met with big excitement all over the world. However, the Pfizer-BioNTech vaccine is based on a new platform, which is still understudied. According to protocol, its trial will be complete only in 2022. IQ talked to Larisa Popovich, Director of the HSE Institute for Health Economics, about the differences between the U.S.-German and the Russian Sputnik V vaccines, and about the chances of beating COVID-19 with massive immunization in the upcoming months.